Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130260 · ClinicalTrials.gov registry record · Phase 3
Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease
A Phase 3 study, sponsored by Nabi Biopharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 99
- Enrollment target
NCT00130260: Clinical Trial Phase 3 study, sponsored by Nabi Biopharmaceuticals.
NCT00130260 is a Phase 3 study that was terminated before completion, run by Nabi Biopharmaceuticals. The registered enrollment target is 99 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00130260, a Phase 3 study, was terminated before completion, sponsored by Nabi Biopharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 99 participants
- Enrollment target
Study Summary
This study is a continued evaluation of the immune response to StaphVAX , a Staphylococcus aureus type 5 and 8 capsular polysaccharide conjugate vaccine, in end-stage renal disease patients, by giving a 3rd and 4th dose to a subset of the participants in the previous efficacy trial. Participants continue to receive the vaccine or placebo in a blinded manner, and are also randomly assigned to 1 of 2 different intervals between the doses. The immunogenicity is measured by the antibodies in the blood, and typical vaccine safety information is also collected.
Interventions
- BIOLOGICAL placebo
- BIOLOGICAL Staph aureus types 5 and 8 conjugate vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2005-08 |
| Est. Completion | 2006-04 |
| Phase | Phase 3 |
Why NCT00130260 stopped before completion
NCT00130260 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00130260 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00130260 about?
NCT00130260 is a clinical study titled "Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease". This study is a continued evaluation of the immune response to StaphVAX , a Staphylococcus aureus type 5 and 8 capsular polysaccharide conjugate vaccine, in end-stage renal disease patients, by giving a 3rd and 4th dose to a subset of the participants in the previous efficacy trial. Participants con...
What is the current status of trial NCT00130260?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 99 participants. The study started on 2005-08. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00130260?
The interventions under investigation include: placebo (BIOLOGICAL), Staph aureus types 5 and 8 conjugate vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00130260?
This trial is sponsored by Nabi Biopharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00130260's enrollment target sits among peer trials
99 1713th of 2000 higher than 287 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia